Nardiello, C.; Mizikova, I.; Morty, R. E.: Looking ahead: where to next for animal models of bronchopulmonary dysplasia? CELL AND TISSUE RESEARCH 367 (3), pp. 457 - 468 (2017)
Nardiello, C.; Mizikova, I.; Silva, D. M.; Ruiz-Camp, J.; Mayer, K.; Vadasz, I.; Herold, S.; Seeger, W.; Morty, R. E.: Standardisation of oxygen exposure in the development of mouse models for bronchopulmonary dysplasia. DISEASE MODELS & MECHANISMS 10 (2), pp. 185 - 196 (2017)
Rath, P.; Nardiello, C.; Solaligue, D. E. S.; Agius, R.; Mizikova, I.; Huehn, S.; Mayer, K.; Vadasz, I.; Herold, S.; Runkel, F.et al.; Seeger, W.; Morty, R. E.: Caffeine administration modulates TGF-beta signaling but does not attenuate blunted alveolarization in a hyperoxia-based mouse model of bronchopulmonary dysplasia. PEDIATRIC RESEARCH 81 (5), pp. 795 - 805 (2017)
Ruiz Camp, J.; Quantius, J.; Arndt, P. D.; Mizikova, I.; Herold, S.; Seeger, W.; Morty, R. E.: Microrna-34a Blockade Partially Restores Normal Septal Thickness In An Experimental Animal Model Of Bronchopulmonary Dysplasia. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 193 (2016)
Ruiz Camp, J.; Quantius, J.; Arndt, P. D.; Mizikova, I.; Herold, S.; Seeger, W.; Morty, R. E.: Microrna-34a Blockade Partially Restores Normal Septal Thickness In An Experimental Animal Model Of Bronchopulmonary Dysplasia. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 193 (2016)
Researchers at the Max Planck Institute develop a new pharmacological approach that specifically targets receptor interactions – with implications for immune defense and blood pressure regulation
A team of researchers at the Max Planck Institute for Heart and Lung Research, led by Prof. Dr. Didier Y.R. Stainier, has been awarded a prestigious ERC Proof of Concept (PoC) grant to advance a groundbreaking RNA-based therapeutic strategy for Duchenne Muscular Dystrophy (DMD).